Menotrophin Ferring (Menotrophin)

Menotrophin contains analogues of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). After subcutaneous injection, the FSH component stimulates granulosa cells to recruit and grow ovarian follicles, while the LH component promotes theca cell androgen production and final follicular maturation, culminating in ovulation.

The specific dose of Menotrophin is individualized and determined by the prescribing physician based on the patient’s ovarian response, treatment protocol, and clinical goals. Dosing regimens can vary widely, and the prescriber will adjust the amount and duration according to monitoring results.

Menotrophin is intended for use before conception to induce ovulation; its safety in established pregnancy has not been established, and it is generally discontinued once pregnancy is confirmed. Limited data exist for use during breastfeeding, so it should be avoided unless the benefits outweigh potential risks as judged by a healthcare professional.

To place an order, submit an enquiry on the Menotrophin Ferring product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Menotrophin uniquely combines both FSH and LH activity in a single preparation, whereas many other gonadotropin products contain only FSH or only LH. This dual action can simplify stimulation protocols and may reduce the number of injections required, but the choice between products depends on individual patient characteristics and clinician preference.

Menotrophin must be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain using validated insulated containers and temperature monitors.

Menotrophin is given by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a trained healthcare professional or a patient who has been instructed on proper aseptic technique, dose preparation, and site rotation to minimize discomfort and local reactions.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause significant ovarian enlargement, fluid shifts, and thromboembolic events, as well as rare allergic reactions such as anaphylaxis. Patients should be monitored closely for abdominal pain, rapid weight gain, shortness of breath, or signs of an allergic response.

Menotrophin is contraindicated in women with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, severe liver or kidney impairment, or known hypersensitivity to the product. It should also be avoided in patients who are already pregnant or who have a history of severe OHSS.